Compare Abbott Laboratories (ABT) vs New York Times Co (NYT) Price & Performance
Price performance
Price movement over the last 24 hours
Key statistics
Key statistics
Abbott Laboratories vs New York Times Co — how do they compare? Abbott Laboratories trades at $95.33 (market cap $166.94B), while New York Times Co trades at $73.31 (market cap $11.93B). The key difference: Abbott Laboratories is far larger — about 14× New York Times Co's market cap, and Abbott Laboratories pays the higher dividend (2.63%). Which is the better fit depends on your goals.
| ABT | NYT | |
|---|---|---|
Market Cap | $166.94B | $11.93B |
Sector | Health | Media |
52-Week High | $136.62 | $85.86 |
52-Week Low | $82.57 | $51.43 |
Enterprise Value | $193.69B | $11.33B |
Dividend Yield | 2.63% | 1.25% |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Abbott Laboratories (ABT) trades at $95.63, up 0.25% on the day, with a bullish technical signal from moving averages and strong analyst support. The stock shows solid fundamentals with a P/E of 26.79 and net income margin of 13.91%, though recent earnings have been mixed. Recent news highlights regulatory approvals for new medical devices, supporting growth prospects.
The outlook remains positive with a consensus price target of $122.55, implying significant upside. Key risks include competitive pressures and macroeconomic headwinds, but strong institutional backing and consistent dividend payments provide stability for long-term investors.
The New York Times Company (NYT) trades at $73.72, showing modest daily movement. The stock exhibits a bullish technical trend with strong moving average signals. Fundamentally, the company demonstrates consistent revenue growth, expanding profit margins, and robust cash flow from operations. Recent quarterly earnings have consistently surpassed analyst expectations, reflecting operational strength. A dividend of $0.23 per share is scheduled for payment in July 2026.
The outlook for NYT is positive, supported by solid financial performance and a 'Buy' analyst consensus with a $78.00 price target, implying potential upside. Key opportunities include sustained digital subscription growth and margin expansion. Primary risks involve competitive pressures in the media landscape and broader economic sensitivity affecting advertising revenue. The stock presents a compelling case for investors seeking a stable, growing media company.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
Top news
Latest headlines on both assets
Top news
Latest headlines on both assets
About Abbott Laboratories
Abbott manufactures and markets medical devices, adult and pediatric nutritional products, diagnostic equipment and testing kits, and branded generic drugs. Products include pacemakers, implantable cardioverter defibrillators, neuromodulation devices, coronary stents, catheters, infant formula, nutritional liquids for adults, molecular diagnostic platforms, and immunoassays and point-of-care diagnostic equipment. Abbott derives approximately 60% of sales outside the United States.
Read more on ABT →About New York Times Co
New York Times Co is an American media company known for publishing its flagship newspaper, The New York Times. The company also operates the International New York Times newspaper, as well as digital properties such as nytimes and various smartphone applications. Circulation of The New York Times is the source of revenue for the company, followed by print and digital advertising and its paid digital-only subscription to The New York Times. The company has a daily print circulation of over 500,000 and 1,000,000 on Sundays. The source of growth for The New York Times is its digital subscription service, which has over 1,000,000 paid users.
Read more on NYT →
